DSpace university logo mark
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 030 医学部 > 030 紀要 > Acta Medica Nagasakiensia > Volume 61, No. 4 >

Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan

ファイル 記述 サイズフォーマット
ActMed61_167.pdf1.01 MBAdobe PDF本文ファイル

タイトル: Intravenous liposomal amphotericin B versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan
著者: Kohno, Shigeru / Izumikawa, Koichi / Ogawa, Kenji / Kurashima, Atsuyuki / Okimoto, Niro / Suzuki, Katsuhiro / Kakeya, Hiroshi / Niki, Yoshihito / Ichihara, Kiyoshi / Miyazaki, Yoshitsugu
発行日: 2018年 3月
出版者: Nagasaki University School of Medicine / 長崎大学医学部
引用: Acta medica Nagasakiensia, 61(4), pp.167-176; 2018
抄録: Chronic pulmonary aspergillosis (CPA) is slowly progressive inflammatory pulmonary syndrome due to infection of Aspergillus spp. We conducted a randomized, multicenter, open-label trial comparing intravenous liposomal amphotericin B (L-AMB) of 2.5-5.0 mg/kg once daily with intravenous voriconazole (VRCZ) of 6 mg/kg twice on Day 1 followed by 4 mg/kg twice daily. Treatment effectiveness was defined by clinical, and radiological improvement at both 2 weeks after the initial administration and at the end of therapy. The total of 166 patients were recruited and 83 patients for each drug group were assigned. Total of 51 and 59 cases of L-AMB and VRCZ, respectively were assessed as per-protocol populations. The difference in efficacy rates between L-AMB and VRCZ was not significant, either after 2 weeks [49.0% vs. 59.3%; the absolute difference, 10.3% with a 95% confidence interval (CI), -8.4 to 29.00, P=0.279] or at the end of therapy (52.9% vs. 67.8%; the absolute difference, 14.9% with a 95% CI, -3.4 to 33.2, P=0.111). In the safety evaluation, no statistical difference of occurrence rates in both LAMB and VRCZ group (54.2% vs. 59.0%, P=0.531). L-AMB was as effective as VRCZ with no significant difference of adverse effects in the treatment of CPA. (UMIN Clinical Trials Registry number, UMIN000002236.)
キーワード: chronic pulmonary aspergillosis / liposomal amphotericin B / voriconazole
URI: http://hdl.handle.net/10069/38193
ISSN: 00016055
関連リンク : http://hdl.handle.net/10069/38673
資料タイプ: Departmental Bulletin Paper
原稿種類: publisher
出現コレクション:Volume 61, No. 4

引用URI : http://hdl.handle.net/10069/38193



Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace